구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | NK cells + PD- (NK cells + PD-, NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy) BOE Technology Group Co., Ltd.·NSCLC (Advanced Non-small Cell Lun… 30 trials |
|---|---|
Overview Program | NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy |
Overview Company | BOE Technology Group Co., Ltd. |
Overview Modality | CGT |
Overview Target | NSCLC (Advanced Non-small Cell Lung Canc |
Overview Indication | NSCLC (Advanced Non-small Cell Lung Cancer); Colorectal Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Polysaccharides: Natural candidates for targeting immunometabolic regulation in hepatocellular carcinoma (Review).. Hepatocellular carcinoma (HCC) is a leading cause of cancer‑related morbidity and mortality worldwide. HCC pathogenesis is predominantly associated with chronic liver disease, driven by a vicious cycle of persistent hepatic injury, chronic inflammation and aberrant hepatocyte … |
Toxicology CRS | Reported |
Clinical Safety signal | Polysaccharides: Natural candidates for targeting immunometabolic regulation in hepatocellular carcinoma (Review).. Hepatocellular carcinoma (HCC) is a leading cause of cancer‑related morbidity and mortality worldwide. HCC pathogenesis is predominantly associated with chronic liver disease, driven by a vicious cycle of persistent hepatic injury, chronic inflammation and aberrant hepatocyte … |
Clinical Selected reported efficacy | ORR 36% |
Clinical Reported ORR | 36% |
Clinical Result source | ClinicalTrials.gov NCT03785925 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03785925 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | NK cells + PD- (NK cells + PD-, NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy) BOE Technology Group Co., Ltd.·NSCLC (Advanced Non-small Cell Lun… 30 trials |
|---|---|
Overview Program | NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy |
Overview Company | BOE Technology Group Co., Ltd. |
Overview Modality | CGT |
Overview Target | NSCLC (Advanced Non-small Cell Lung Canc |
Overview Indication | NSCLC (Advanced Non-small Cell Lung Cancer); Colorectal Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Polysaccharides: Natural candidates for targeting immunometabolic regulation in hepatocellular carcinoma (Review).. Hepatocellular carcinoma (HCC) is a leading cause of cancer‑related morbidity and mortality worldwide. HCC pathogenesis is predominantly associated with chronic liver disease, driven by a vicious cycle of persistent hepatic injury, chronic inflammation and aberrant hepatocyte … |
Toxicology CRS | Reported |
Clinical Safety signal | Polysaccharides: Natural candidates for targeting immunometabolic regulation in hepatocellular carcinoma (Review).. Hepatocellular carcinoma (HCC) is a leading cause of cancer‑related morbidity and mortality worldwide. HCC pathogenesis is predominantly associated with chronic liver disease, driven by a vicious cycle of persistent hepatic injury, chronic inflammation and aberrant hepatocyte … |
Clinical Selected reported efficacy | ORR 36% |
Clinical Reported ORR | 36% |
Clinical Result source | ClinicalTrials.gov NCT03785925 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03785925 |
추천 비교
추천 비교